SRR12475120
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.380
- ANDROGEN_RESPONSE+0.330
- PROTEIN_SECRETION+0.320
- MITOTIC_SPINDLE+0.190
- MYC_TARGETS_V1+0.170
- TGF_BETA_SIGNALING+0.170
- CHOLESTEROL_HOMEOSTASIS+0.150
- SPERMATOGENESIS+0.150
- MTORC1_SIGNALING+0.130
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.370
- MYOGENESIS-0.350
- ALLOGRAFT_REJECTION-0.290
- COAGULATION-0.280
- OXIDATIVE_PHOSPHORYLATION-0.250
- NOTCH_SIGNALING-0.240
- HYPOXIA-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8ca13509-abad-46b7-92f4-fa741bc52b42 | — | — | 0.856 |
| 2 | TCGA-AO-A1KS-01A-11R-A13Q-07 | — | B | 0.839 |
| 3 | 2c343b93-910c-4921-bc2b-f7fbfa4f1596 | — | — | 0.836 |
| 4 | MDT-AP-3021 | Med | Medulloblastoma | 0.836 |
| 5 | TCGA-A2-A1FW-01A-11R-A13Q-07 | — | B | 0.824 |
| 6 | MDT-AP-3402 | Med | Medulloblastoma | 0.823 |
| 7 | MDT-AP-3017 | Med | Medulloblastoma | 0.822 |
| 8 | 680dcf75-8d74-45ca-b1d6-0ef7310e6473 | — | — | 0.819 |
| 9 | MDT-AP-0184 | Med | Medulloblastoma | 0.814 |
| 10 | TCGA-A2-A1G4-01A-11R-A13Q-07 | — | B | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |